Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes
Sanofi-aventis announced results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus(R) (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy (OADs), was associated with a greater reduction in A1C levels and lower incidence of any hypoglycemia versus all comparators (OADs, NPH, lispro, premix).
http://www.prnewswire.co.uk/cgi/release?id=297723
See also:
Investigational Drug Dapagliflozin For Diabetes Meets Study Goals After 24-Week Phase 3 Study
Dapagliflozin when added to existing glimepiride (sulphonylurea) therapy significantly reduced HbA1C (glycosylated hemoglobin) in adults with Type 2 Diabetes, compared to patients taking glimepiride plus a placebo, a 24-week Phase 3 Study revealed. In a joint announcement, Astra Zeneca PLC. and Bristol-Myers Squibb Company said the trial met the study goals.
http://www.medilexicon.com/medicalnews.php?newsid=201796
Sanofi-aventis announced results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus(R) (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy (OADs), was associated with a greater reduction in A1C levels and lower incidence of any hypoglycemia versus all comparators (OADs, NPH, lispro, premix).
http://www.prnewswire.co.uk/cgi/release?id=297723
See also:
Investigational Drug Dapagliflozin For Diabetes Meets Study Goals After 24-Week Phase 3 Study
Dapagliflozin when added to existing glimepiride (sulphonylurea) therapy significantly reduced HbA1C (glycosylated hemoglobin) in adults with Type 2 Diabetes, compared to patients taking glimepiride plus a placebo, a 24-week Phase 3 Study revealed. In a joint announcement, Astra Zeneca PLC. and Bristol-Myers Squibb Company said the trial met the study goals.
http://www.medilexicon.com/medicalnews.php?newsid=201796
